Dr. Fu currently is a Senior Chair Professor of West China Hospital, and
Dean, Institution of Immunology and Inflammation, Sichuan University, China
Received his PhD in molecular biology at Columbia University in 1988 (Mentor: James Manley)
Postdoctoral training at Rockefeller University with James Darnell (1988-1991)
Assistant Professor at Mt Sinai School of Medicine NY (1992-1994)
Assistant & Associate Professor at Yale University (1994-2003)
Full Professor at Indiana University (2004-2015).
Founding director of Tsinghua Institute of Genome Research of Tsinghua University, China (2000-2006).
Head (2008-2011) and Professor (2008-2019) of Department of Biochemistry of National University of Singapore
Senior Principal Investigator, Singapore Cancer Science Institute, Singapore (2008 – 2019)
Dr Fu and his colleagues discovered the STAT gene family and the JAK-STAT signaling Pathway (Fu and Darnell et al, PNAS 89:7840-7843, 1992; Fu, Cell, 70:323-335, 1992). He has made a number of seminal discoveries in molecular mechanisms of mammalian development, immunity and diseases in the past 30 years. Particularly, since Dr Fu's original discovery, there are about 100,000 publications on the JAK-STAT pathway, and over 12 FDA approved drugs against the JAK-STAT. In the past 12 years,
Dr Fu’s laboratory has focused on STAT's role in regulation of inflammation, development and cancer.
GenEros BioPharma is a cutting-edge drug discovery company founded by Dr Xin-Yuan Fu in 2015. GenEros pipelines focus on precision of medicine across inflammatory diseases and cancer. The company now have four clinical trials worldwide aiming at creating FIC or BIC small molecular drugs for unmet medical needs in major inflammatory diseases and late stage cancers.
